The European Medicines Agency (EMA) has approved the use of an artificial intelligence (AI) tool, AIM-NASH, to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH) in...
The European Medicines Agency (EMA) has approved the use of an artificial intelligence (AI) tool, AIM-NASH, to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH) in...